These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 31469968

  • 1. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
    Federman N, McDermott R.
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
    [Abstract] [Full Text] [Related]

  • 2. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 3. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
    Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J.
    BMC Cancer; 2022 Jun 07; 22(1):625. PubMed ID: 35672677
    [Abstract] [Full Text] [Related]

  • 4. Larotrectinib for the treatment of TRK fusion solid tumors.
    Laetsch TW, Hawkins DS.
    Expert Rev Anticancer Ther; 2019 Jan 07; 19(1):1-10. PubMed ID: 30350734
    [Abstract] [Full Text] [Related]

  • 5. Larotrectinib: First Global Approval.
    Scott LJ.
    Drugs; 2019 Feb 07; 79(2):201-206. PubMed ID: 30635837
    [Abstract] [Full Text] [Related]

  • 6. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW.
    Cancer; 2023 Dec 01; 129(23):3772-3782. PubMed ID: 37769113
    [Abstract] [Full Text] [Related]

  • 7. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
    Filippi R, Depetris I, Satolli MA.
    Expert Opin Pharmacother; 2021 Apr 01; 22(6):677-684. PubMed ID: 33576301
    [Abstract] [Full Text] [Related]

  • 8. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 01; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 9. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [Abstract] [Full Text] [Related]

  • 10. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
    Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Geoerger B, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A, Hong DS.
    Curr Probl Cancer; 2021 Dec 01; 45(6):100734. PubMed ID: 33865615
    [Abstract] [Full Text] [Related]

  • 11. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 01; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer.
    Laetsch TW, Hong DS.
    Clin Cancer Res; 2021 Sep 15; 27(18):4974-4982. PubMed ID: 33893159
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.
    Kheder ES, Hong DS.
    Clin Cancer Res; 2018 Dec 01; 24(23):5807-5814. PubMed ID: 29986850
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
    Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME.
    Eur J Endocrinol; 2022 Apr 29; 186(6):631-643. PubMed ID: 35333737
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
    Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S, Meric-Bernstam F, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC.
    Ann Oncol; 2019 Feb 01; 30(2):325-331. PubMed ID: 30624546
    [Abstract] [Full Text] [Related]

  • 20. Dramatic Responses Seen with TRK Inhibitor.
    Cancer Discov; 2017 Aug 01; 7(8):787. PubMed ID: 28583910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.